A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

NCT05659537 · Completed

Last updated 2026-05-28

This clinical trial tested the safety of the medication dulaglutide in adults with type 2 diabetes in India by monitoring side effects, serious health issues, and deaths.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 212 people

Who can join Ages 18+ · all sexes

Timeline Started 2022-12 · est. completion 2024-01

Where 7 sites · India

What this study is testing ClinicalTrials.gov NCT05659537 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in India.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SC

Main thing measured	Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Deaths
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05659537 ↗